Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
Type
Public
HQ
Chandler, US
Founded
1998
Size (employees)
510 (est)
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US

Key People at Insys Therapeutics

Michael L. Babich

Michael L. Babich

CEO
Darryl S. Baker

Darryl S. Baker

CFO
Larry Dillaha

Larry Dillaha

CMO

Insys Therapeutics Office Locations

Insys Therapeutics has an office in Chandler
Chandler, US (HQ)
444 S Ellis Rd

Insys Therapeutics Data and Metrics

Insys Therapeutics Financial Metrics

Insys Therapeutics's revenue was reported to be $330.8 m in FY, 2015 which is a 49% increase from the previous period.
$, USD

Revenue (FY, 2015)

330.8 m

Revenue growth (FY, 2014 - FY, 2015), %

49%

Gross profit (FY, 2015)

301.9 m

Gross profit margin (FY, 2015), %

91%

Net income (FY, 2015)

58.5 m

EBIT (FY, 2015)

92.4 m

Market capitalization (23-Jun-2017)

989.6 m

Closing share price (23-Jun-2017)

13.1

Cash (31-Dec-2015)

79.5 m
Insys Therapeutics's current market capitalization is $989.6 m.
$, USDFY, 2013FY, 2014FY, 2015

Revenue

99.3 m222.1 m330.8 m

Revenue growth, %

124%49%

Cost of goods sold

12.7 m28.9 m

Gross profit

86.6 m199.5 m301.9 m

Gross profit Margin, %

87%90%91%

Operating expense total

54.1 m135.5 m209.5 m

EBIT

32.6 m64 m92.4 m

EBIT margin, %

33%29%28%

Interest expense

928 k

Interest income

502 k

Pre tax profit

31.6 m93 m

Income tax expense

8.8 m

Net Income

40.4 m38 m58.5 m
$, USDFY, 2013FY, 2014FY, 2015

Cash

45.4 m58.1 m79.5 m

Inventories

14.5 m34.8 m41.7 m

Current Assets

82.2 m151 m253.2 m

PP&E

10.1 m38.4 m

Total Assets

100.6 m215.1 m351.2 m

Accounts Payable

16.6 m27.5 m36.4 m

Current Liabilities

21.1 m45.7 m88.9 m

Common Stock

354 k719 k

Additional Paid-in Capital

168.5 m216.4 m245.7 m

Retained Earnings

(89 m)(51.1 m)7.4 m

Total Equity

79.5 m165.7 m253.7 m

Financial Leverage

1.3 x1.3 x1.4 x
$, USDFY, 2013FY, 2014FY, 2015

Net Income

40.4 m58.5 m

Depreciation and Amortization

1.8 m2.5 m5.3 m

Accounts Receivable

(13 m)(10 m)(22 m)

Inventories

(7.4 m)(20 m)(6.9 m)

Cash From Operating Activities

24.2 m49.7 m100.9 m

Purchases of PP&E

(5.1 m)(22.2 m)(13.8 m)

Cash From Investing Activities

(5.5 m)(69.9 m)(88.7 m)

Cash From Financing Activities

26.3 m32.9 m9.3 m

Income Taxes Paid

991 k3 m15.4 m
$, USDY, 2015

Revenue/Employee

648.6 k

Financial Leverage

1.4 x

Insys Therapeutics Market Value History

Insys Therapeutics Median Salaries

Source: 24 public H-1B filings from Insys Therapeutics

Insys Therapeutics News and Updates

Insys Therapeutics Company Life and Culture

You may also be interested in